Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TTRX
TTRX logo

TTRX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Turn Therapeutics Inc (TTRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.510
1 Day change
2.84%
52 Week Range
26.500
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

TTRX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has short-term technical strength, but the overbought RSI, lack of recent news, no clear fundamental data, neutral insider/hedge fund activity, and no proprietary buy signal make this an unattractive immediate entry. Since the user is impatient and wants a direct answer, the best call is to hold off and wait for a better setup.

Technical Analysis

Price is 5.3 in regular trading and unchanged on the day, but pre-market is down 3.01%, which weakens near-term momentum. Technically, the stock is still in a bullish structure because SMA_5 is above SMA_20 and SMA_20 is above SMA_200, and MACD histogram is positive at 0.1. However, RSI_6 is 80.191, which is overbought and suggests the move may be stretched. The pivot is 4.743 with resistance at 5.39 and 5.79, so the current price is already near the first resistance zone. Overall trend is bullish but extended, making it a poor fresh entry for a long-term beginner right now.

Positive Catalysts

  • Bullish moving average alignment remains intact. MACD is positive. Similar candlestick pattern analysis suggests modest upside probabilities over the next day, week, and month. There are no recent negative news items, and the stock is holding above its pivot level.

Neutral/Negative Catalysts

  • RSI is overbought at 80.191, suggesting limited immediate upside. Pre-market weakness is -3.01%, which may indicate early selling pressure. There is no recent news catalyst, no meaningful analyst update, no valuation support, no recent insider buying, no significant hedge fund accumulation, and no congress trading activity.

Financial Performance

No usable latest-quarter financial snapshot was available because the provided financial data returned an error. As a result, there is no reliable quarter-over-quarter revenue or earnings growth assessment to support a long-term buy decision. Latest quarter season could not be identified from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data was provided, so there is no recent Wall Street upgrade, downgrade, or target revision trend to assess. Based on the available information, Wall Street sentiment cannot be confirmed as bullish, and the lack of analyst support reduces conviction.

Wall Street analysts forecast TTRX stock price to rise
3 Analyst Rating
Wall Street analysts forecast TTRX stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.330
sliders
Low
6.15
Averages
6.77
High
8
Current: 6.330
sliders
Low
6.15
Averages
6.77
High
8
Boral Capital
D. Boral
Buy
initiated
$8
AI Analysis
2025-12-29
Reason
Boral Capital
D. Boral
Price Target
$8
AI Analysis
2025-12-29
initiated
Buy
Reason
D. Boral Capital initiated coverage of Turn Therapeutics with a Buy rating and $8 price target. Turn is developing a dermatology-focused therapeutic platform to address inflammatory and immune-mediated skin diseases with high unmet need, the analyst tells investors in a research note. The firm says the company has both near-term clinical readouts and longer-term expansion opportunities across dermatology and related inflammatory indications. Turn's lead programs target conditions where current standards of care are limited by safety, tolerability, or inconsistent efficacy, contends D. Boral.

People Also Watch